Welcome to our dedicated page for Zynex SEC filings (Ticker: ZYXI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zynex, Inc. (ZYXI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K, and other documents filed with the U.S. Securities and Exchange Commission. Zynex is a medical technology company that develops, manufactures, markets, and sells non-invasive medical devices for pain management and rehabilitation, along with non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for hospitals. Its filings offer detailed insight into this business focus, its financial condition, and its capital structure.
For ZYXI, annual reports on Form 10-K and quarterly reports on Form 10-Q describe revenue from devices and supplies, operating expenses, impairment charges, and risk factors. In 2025, the company also filed a Form 12b-25 explaining a delay in filing its third-quarter Form 10-Q and indicating that it expected to disclose substantial doubt about its ability to continue as a going concern, citing limited cash resources and the impact of payer-related issues.
Current reports on Form 8-K are especially important for understanding Zynex’s recent developments. These filings include disclosures about leadership changes, strategic initiatives, impairment charges at Zynex Monitoring Solutions, and, critically, the company’s voluntary Chapter 11 filings in the United States Bankruptcy Court for the Southern District of Texas. Related 8-Ks describe a restructuring support agreement with holders of its 5.00% Convertible Senior Notes due 2026, details of a debtor-in-possession financing facility, and Nasdaq’s determination to delist Zynex’s common stock as a result of the Chapter 11 cases.
Stock Titan’s platform surfaces these filings in real time as they are posted to EDGAR and pairs them with AI-powered summaries that explain key points in clear language. Users can quickly see what each 8-K addresses, how a 10-K or 10-Q discusses revenue trends, impairment charges, or going-concern language, and where documents reference restructuring milestones and listing status. The filings page also helps users locate information related to Zynex’s convertible notes, debtor-in-possession obligations, and other material agreements disclosed in its reports.
For those analyzing ZYXI, this page offers a structured way to review Zynex’s regulatory history, from its medical device business description to its Chapter 11 restructuring steps and Nasdaq delisting process, with AI-generated highlights to reduce the time needed to interpret complex filings.
Zynex announced a significant workforce reduction on June 18, 2025, cutting 86 corporate positions, representing 14% of its total workforce. The restructuring is expected to generate $5 million in annualized cost savings.
Key financial impacts include:
- Total restructuring costs estimated at $0.2 million, primarily for employee severance
- Costs to be recognized in Q2 2025
- Majority of payments expected in Q2 and Q3 2025
The company also addressed an ongoing Tricare payment suspension, noting that while they have appealed the temporary suspension, no response has been received. Zynex emphasized that the workforce reduction is part of a planned adjustment in order processing and billing strategy, unrelated to the Tricare situation.